Alkermes receives orphan drug status for alixorexton in U.S. and Europe
Go back to Alkermes receives orphan drug status for alixorexton in U.S. and Europe| ALKERMES (NASDAQ: ALKS) | Delayed: 45.49 -0.61 (1.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.10 | 52 Week High | $80.71 | |||
| Open | $45.20 | 52 Week Low | $27.14 | |||
| Day High | $46.53 | P/E | 349.92 | |||
| Day Low | $44.63 | EPS | $0.13 | |||
| Volume | 1,355,810 | |||||
